Patrick Scannon MD, PhD

Dr. Pat Scannon is Chief Biotechnology Officer, Executive Vice President and a member of the Board of XOMA Ltd., a biopharmaceutical company focused on the discovery, development and manufacture of therapeutic antibody and other therapeutic proteins. Under Dr. Scannon's technical leadership, XOMA has identified, developed, tested and scaled-up numerous monoclonal antibodies. A Board-certified internist, Dr. Scannon is also a member of the American College of Physicians. He is also currently a member of the Defense Sciences Research Council, an advisory board for the Defense Advanced Research Projects Agency and a member of the Department of Defense's Threat Reduction Advisory Committee, where he is Chair of the ChemBioWarfare Defense Panel. Dr. Scannon holds a Ph.D. in organic chemistry from the University of California, Berkeley and a medical degree from the Medical College of Georgia.

Independent Director